Nebulized antibiotics in mechanically ventilated patients: roadmap and challenges

Expert Review of Anti-Infective Therapy

Volumn 15, Issue 3, 2017, Pages 211-229

  Poulakou, G ^a   Siakallis, G ^a   Tsiodras, S ^a   Arfaras Melainis, A ^a   Dimopoulos, G ^a  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

aminoglycosides; colistin; fosfomycin; Gram negative bacteria; hospital acquired pneumonia; inhaled antibiotics; multidrug resistance; nebulizers; ventilator associated pneumonia; ventilator associated tracheobronchitis

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; COLISTIN; FOSFOMYCIN; POLYMYXIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ARTIFICIAL VENTILATION; BACTERIAL COLONIZATION; CLINICAL PRACTICE; DRUG EFFICACY; HOSPITAL INFECTION; HUMAN; LUNG INFECTION; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NEBULIZER; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW (TOPIC); VENTILATED PATIENT; VENTILATOR ASSOCIATED PNEUMONIA; INHALATIONAL DRUG ADMINISTRATION; MECHANICAL VENTILATOR; RESPIRATORY TRACT INFECTION;

ADMINISTRATION, INHALATION; ANTI-BACTERIAL AGENTS; HUMANS; NEBULIZERS AND VAPORIZERS; PRACTICE GUIDELINES AS TOPIC; RESPIRATORY TRACT INFECTIONS; VENTILATORS, MECHANICAL;

EID: 85013080998     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1080/14787210.2017.1268052     Document Type: Review

References (130)

1. Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia:2016 clinical practice guidelines by the infectious diseases society of america and the American thoracic society. Clin Infect Dis. 2016 Sep;1(63):575–582.•• An important publication which resets our understanding in VAP and HAP and conceptualizes current therapeutic and diagnostic trends
2. Dudeck MA, Weiner LM, Allen-Bridson K, et al. National healthcare safety network (NHSN) report, data summary for 2012, device-associated module. Am J Infect Control. 2013 Dec;41(12):1148–1166.
3. Wang Y, Eldridge N, Metersky ML, et al. National trends in patient safety for four common conditions, 2005–2011. N Engl J Med. 2014 Jan 23;370(4):341–351.
4. Melsen WG, Rovers MM, Groenwold RH, et al. Attributable mortality of ventilator-associated pneumonia:a meta-analysis of individual patient data from randomised prevention studies. Lancet Infect Dis. 2013 Aug;13(8):665–671.
5. Chastre J, Wunderink R, Prokocimer P, et al. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia:a multicenter, randomized study. Crit Care Med. 2008 Apr;36(4):1089–1096.
6. Awad SS, Rodriguez AH, Chuang YC, et al. A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia. Clin Infect Dis. 2014 Jul 1;59(1):51–61.
7. Luna C, Aruj P, Niederman M, et al. Appropriateness and delay to initiate therapy in ventilator-associated pneumonia. Eur Respir J. 2006 Jan;27(1):158–164.
8. Bercault N, Boulain T., Mortality rate attributable to ventilator-associated nosocomial pneumonia in an adult intensive care unit:a prospective case–control study. Crit Care Med. 2001 Dec;29(12):2303–2309.
9. Boucher H, Talbot G, Bradley J, et al. Bad bugs, no drugs:no ESKAPE! an update from the infectious diseases society of America. Clin Infect Dis. 2009 Jan;48(1):1–12.
10. Bassetti M, De Waele JJ, Eggimann P, et al. Preventive and therapeutic strategies in critically ill patients with highly resistant bacteria. Intensive Care Med. 2015 May;41(5):776–795.• An important publication with a future view of preventive and therapeutic strategies in the era of MDR and XDR pathogens causing infections in severely ill patients admitted in ICU departments
11. Rodvold KA, George JM, Yoo L. Penetration of anti-infective agents into pulmonary epithelial lining fluid:focus on antibacterial agents. Clin. Pharmacokinet. 2011 Oct;50(10):637–664.
12. Drlica K, Zhao X. Mutant selection window hypothesis updated. Clin Infect Dis. 2007 Mar 1;44(5):681–688.
13. Honeybourne D, Baldwin DR. The site concentrations of antimicrobial agents in the lung. J Antimicrobial Chemother. 1992 Sep;30(3):249–260.
14. Palmer LB. Ventilator-associated infection:the role for inhaled antibiotics. Curr Opin Pulm Med. 2015 May;21(3):239–249.
15. Gil-Perotin S, Ramirez P, Marti V, et al. Implications of endotracheal tube biofilm in ventilator-associated pneumonia response:a state of concept. Crit Care. 2012 May 23;16(3):R93.
16. Burkhardt O, Rauch K, Kaever V, et al. Tigecycline possibly underdosed for the treatment of pneumonia:a pharmacokinetic viewpoint. Int J Antimicrob Agents. 2009 Jul;34(1):101–102.
17. Roberts JA, Paul SK, Akova M, et al. DALI Study. DALI:defining antibiotic levels in intensive care unit patients:are current β-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis. 2014 Apr;58(8):1072–1083.
18. Pogue JM, Lee J, Marchaim D, et al. Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system. Clin Infect Dis. 2011 Nov;53(9):879–884.
19. Prince AS. Biofilms, antimicrobial resistance, and airway infection. N Engl J Med. 2002 Oct 3;347(14):1110–1111.
20. Waters V, Smyth A. Cystic fibrosis microbiology:advances in antimicrobial therapy. J Cyst Fibros. 2015 Sep;14(5):551–560.
21. Goldstein I, Wallet F, Nicolas-Robin A, et al. Lung deposition and efficiency of nebulized amikacin during Escherichia coli pneumonia in ventilated piglets. Am J Respir Crit Care Med. 2002 Nov 15;166(10):1375–1381.
22. Goldstein I, Wallet F, Robert J, et al. Lung tissue concentrations of nebulized amikacin during mechanical ventilation in piglets with healthy lungs. Am J Respir Crit Care Med. 2002 Jan 15;165(2):171–175.
23. Ferrari F, Lu Q, Girardi C, et al. Nebulized ceftazidime in experimental pneumonia caused by partially resistant Pseudomonas aeruginosa. Intensive Care Med. 2009 Oct;35(10):1792–1800.
24. Palmer LB, Smaldone GC, Chen JJ, et al. Aerosolized antibiotics and ventilator-associated tracheobronchitis in the intensive care unit. Crit Care Med. 2008 Jul;36(7):2008–2013.
25. Palmer LB, Smaldone GC. Reduction of bacterial resistance with inhaled antibiotics in the intensive care unit. Am J Respir Crit Care Med. 2014 May 15; 189(10):1225–1233.•• A landmark study demonstrating the decrease in resistance by use of a well-standardized protocol of antibiotic nebulization in patients with VAT
26. Lu Q, Girardi C, Zhang M, et al. Nebulized and intravenous colistin in experimental pneumonia caused by Pseudomonas aeruginosa. Intensive Care Med. 2010 Jul;36(7):1147–1155.
27. Le J, Ashley ED, Neuhauser MM, et al. Consensus summary of aerosolized antimicrobial agents:application of guideline criteria. Pharmacotherapy. 2010 Jun;30(6):562–584.
28. Lu Q, Yang J, Liu Z, et al. Nebulized ceftazidime and amikacin in ventilator-associated pneumonia caused by Pseudomonas aeruginosa. Am J Respir Crit Care Med. 2011 Jul 1;184(1):106–115.• A very important study with significant contribution to the understanding of the efficacy of nebulized antibiotics in VAP
29. Mojoli F, Iotti GA, Imberti R, et al. The importance of protecting the mechanical ventilator during colistin methanesulfonate nebulization. Intensive Care Med. 2013 Mar;39(3):535–536.
30. Eschenbacher WL, Boushey HA, Sheppard D. Alteration in osmolarity of inhaled aerosols cause bronchoconstriction and cough, but absence of a permeant anion causes cough alone. Am Rev Respir Dis. 1984 Feb;129(2):211–215.
31. Luyt CE, Clavel M, Guntupalli K, et al. Pharmacokinetics and lung delivery of PDDS-aerosolized amikacin (NKTR-061) in intubated and mechanically ventilated patients with nosocomial pneumonia. Crit Care. 2009;13(6):R200.
32. Luyt CE, Eldon MA, Stass H, et al. Pharmacokinetics and tolerability of amikacin administered as BAY41-6551 aerosol in mechanically ventilated patients with gram-negative pneumonia and acute renal failure. J Aerosol Med Pulm Drug Deliv. 2011 Aug;24(4):183–190.
33. Byron PR. Physicochemical effects on lung disposition of pharmaceutical aerosols. Aerosol Sci Tech. 1993;18:223–229.
34. Montgomery AB, Pitlick WH, Nardella P, et al. Sputum concentrations and systemic pharmacokinetics of aerosolized tobramycin (Tobi) in diseased lungs. Respir Drug Deliv. 2000;1:19–24.
35. Rouby JJ, Bouhemad B, Monsel A, et al., the Nebulized Antibiotics Study Group. Aerosolized antibiotics for ventilator-associated pneumonia:lessons from experimental studies. Anesthesiology. 2012 Dec; 117(6):1364–1380.
36. McCoy KS. Compounded colistimethate as possible cause of fatal acute respiratory distress syndrome. N Engl J Med. 2007 Nov 29;357(22):2310–2311.
37. Pritchard JN. The influence of lung deposition on clinical response. J Aerosol Med. 2001;14(Suppl 1):19–26.
38. Dhand R. Aerosol delivery during mechanical ventilation:from basic techniques to new devices. J Aerosol Med Pulm Drug Deliv. 2008 Mar;21(1):45–60.
39. Bassetti M, Luyt CE, Nicolau DP, et al. Characteristics of an ideal nebulized antibiotic for the treatment of pneumonia in the intubated patient. Ann Intensive Care. 2016 Dec;6(1):35.
40. Ehrmann S, Lyazidi A, Louis B, et al. Ventilator-integrated jet nebulization systems:tidal volume control and efficiency of synchronization. Respir Care. 2014 Oct;59(10):1508–1516.
41. Ari A, Areabi H, Fink JB. Evaluation of aerosol generator devices at 3 locations in humidified and non-humidified circuits during adult mechanical ventilation. Respir Care. 2010 Jul;55(7):837–844.
42. Kadrichu N, Boc S, Corkery K, et al. In vitro efficiency of the Amikacin Inhale System, a novel integrated drug-device delivery system. Isicem. 2013 Mar 19–22:Poster A384.
43. Laube B, Janssens H, De Jongh F, et al. What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J. 2011 Jun;37(6):1308–1331.
44. Ari A, Atalay OT, Harwood R, et al. Influence of nebulizer type, position, and bias flow on aerosol drug delivery in simulated pediatric and adult lung models during mechanical ventilation. Respir Care. 2010;55(7):845–851.
45. Clinicaltrials.gov, available from:https://clinicaltrials.gov/ct2/show/NCT01969799 Accessed 2 Aug 2016
46. PARI eFlow rapid, Technical Data. Available from:http://www.pari.de/uk-en/products/lower-airways-1/eflow-rapid-nebuliser-system-1/Accessed 2 Aug 2016
47. Montgomery A, Rhomberg P, Abuan T, et al. Amikacin-fosfomycin at a five-to-two ratio:characterization of mutation rates in microbial strains causing ventilator-associated pneumonia and interactions with commonly used antibiotics. Antimicrob Agents Chemother. 2014 Jul;58(7):3708–3713.
48. Montgomery A, Rhomberg P, Abuan T, et al. Potentiation effects of amikacin and fosfomycin against selected amikacin-non susceptible Gram-negative respiratory tract pathogens. Antimicrob Agents Chemother. 2014 Jul;58(7):3714–3719.
49. Montgomery A, Vallance S, Abuan T, et al. A randomized double-blind placebo-controlled dose-escalation Phase 1 study of aerosolized amikacin and fosfomycin delivered via the PARI Investigational eFlow® Inline Nebulizer System in mechanically ventilated patients. J Aerosol Med Pulm Drug Deliv. 2014 Dec;27(6):441–448.
50. Miller DD, Amin MM, Palmer LB, et al. Aerosol delivery and modern mechanical ventilation:in vitro/in vivo evaluation. Am J Respir Crit Care Med. 2003 Nov 15;168(10):1205–1209.
51. Phipps PR, Gonda I. Droplets produced by medical nebulizers. Some factors affecting their size and solute concentration. Chest. 1990 Jun;97(6):1327–1332.
52. Rao N, Kadrichu N, Ament B. Application of a droplet evaporation model to aerodynamic size measurement of drug aerosols generated by a vibrating mesh nebulizer. J Aerosol Med Pulm Drug Deliv. 2010 Oct;23(5):295–302.
53. Lu Q, Luo R, Bodin L, et al. Nebulized Antibiotics Study Group. Efficacy of high-dose nebulized colistin in ventilator-associated pneumonia caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Anesthesiology. 2012 Dec;117(6):1335–1347.•• A pilot study which has opened the field of high-dose nebulized colistin, proving clinical efficacy and safety as monotherapy
54. Dolovich MB, Dhand R. Aerosol drug delivery:developments in device design and clinical use. Lancet. 2011 Mar 19;377(9770):1032–1045.
55. Weers J. Inhaled antimicrobial therapy–barriers to effective treatrment. Adv Drug Deliv Rev. 2015 May;85:24–43.
56. Berlana D, Llop JM, Fort E, et al. Use of colistin in the treatment of multipledrug- resistant gram-negative infections. Am J Health Syst Pharm. 2005;62:39–47.
57. Pereira GH, Muller PR, Levin AS. Salvage treatment of pneumonia and initial treatment of tracheobronchitis caused by multidrug-resistant gram-negative bacilli with inhaled polymyxin B. Diagn Microbiol Infect Dis. 2007 Jun;58(2):235–240.
58. Michalopoulos A, Fotakis D, Virtzili S, et al. Aerosolized colistin as adjunctive treatment of ventilator-associated pneumonia due to multidrug-resistant gram-negative bacteria:a prospective study. Respir Med. 2008;102:407–412.
59. Ganapathy H, Pal SK, Teare L, et al. Use of colistin in treating multi-resistant gram-negative organisms in a specialised burns unit. Burns. 2010 Jun;36(4):522–527.
60. Lin CC, Liu TC, Kuo CF, et al. Aerosolized colistin for the treatment of multidrug-resistant acinetobacter baumannii pneumonia:experience in a tertiary care hospital in northern Taiwan. J Microbiol Immunol Infect. 2010 Aug;43(4):323–331.
61. Korbila IP, Michalopoulos A, Rafailidis PI, et al. Inhaled colistin as adjunctive therapy to intravenous colistin for the treatment of microbiologically documented ventilator-associated pneumonia:a comparative cohort study. Clin Microbiol Infect. 2010;16:1230–1236.
62. Rattanaumpawan P, Lorsutthitham J, Ungprasert P, et al. Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy ofventilator-associated pneumonia caused by gram-negative bacteria. J Antimicrob Chemother. 2010;65:2645–2649.
63. Kofteridis DP, Alexopoulou C, Valachis A, et al. Aerosolized plus intravenous colistin versus intravenous colistin alone for the treatment of ventilator-associated pneumonia:a matched case-control study. Clin Infect Dis. 2010 Dec 1;51(11):1238–1244.
64. Athanassa ZE, Myrianthefs PM, Boutzouka EG, et al. Monotherapy with inhaled colistin for the treatment of patients with ventilator-associated tracheobronchitis due to polymyxin-only-susceptible Gram-negative bacteria. J Hosp Infect. 2011 Aug;78(4):335–336.
65. Naesens R, Vlieghe E, Verbrugghe W, et al. A retrospective observational study on the efficacy of colistin by inhalation as compared to parenteral administration for the treatment of nosocomial pneumonia associated with multidrug-resistant pseudomonas aeruginosa. BMC Infect Dis. 2011;11:317.
66. Pérez-Pedrero MJ, Sánchez-Casado M, Rodríguez-Villar S. Nebulized colistin treatment of multi-resistant acinetobacter baumannii pulmonary infection in critical ill patients. Med Intensiva. 2011;35:226–231.
67. Arnold HM, Sawyer AM, Kollef MH. Use of adjunctive aerosolized antimicrobial therapy in the treatment of pseudomonas aeruginosa and acinetobacter baumannii ventilator-associated pneumonia. Respir Care. 2012;57:1226–1233.
68. Kalin G, Alp E, Coskun R, et al. Use of high-dose IV and aerosolized colistin for the treatment of multidrug-resistant acinetobacter baumannii ventilator-associated pneumonia:do we really need this treatment? J Infect Chemother. 2012 Dec;18(6):872–877.
69. Kuo SC, Lee YT, Yang SP, et al. Eradication of multidrug-resistant acinetobacter baumannii from the respiratory tract with inhaled colistin methanesulfonate:a matched case-control study. Clin Microbiol Infect. 2012 Sep;18(9):870–876.
70. Tumbarello M, De Pascale G, Trecarichi EM, et al. Effect of aerosolized colistin as adjunctive treatment on the outcomes of microbiologically documented ventilator-associated pneumonia caused by colistin-only susceptible gram negative bacteria. Chest. 2013;144:1768–1775.• One of the largest studies which despite its retrospective nature has shown some clear conclusions about the efficacy of nebulized colistin as an add-on strategy in VAP caused by colistin-only bacteria
71. Doshi NM, Cook CH, Mount KL, et al. Adjunctive aerosolized colistin for multidrug resistant gram-negative pneumonia in the critically ill:a retrospective study. BMC Anesthesiol. 2013;13:45.
72. Bogovic TZ, Budimir A, Bosnjak Z, et al. Inhalation plus intravenous colistin versus intravenous colistin alone for treatment of ventilator associated pneumonia. Signa Vitae. 2014;9:29–33.
73. Abdellatif S, Trifi A, Daly F, et al. Efficacy and toxicity of aerosolised colistin in ventilator-associated pneumonia:a prospective, randomised trial. Ann Intensive Care. 2016 Dec;6(1):26.
74. Mohr AM, Sifri ZC, Hornq HS, et al. Use of aerosolized aminoglycosides in the treatment of gram-negative ventilator-associated pneumonia. Surg Infect (Larchmt). 2007 Jun;8(3):349–357.
75. Czosnowski QA, Wood GC, Magnotti LJ, et al. adjunctive aerosolized antibiotics for treatment of ventilator-associated pneumonia. Pharmacotherapy. 2009 Sep;29(9):1054–1060.
76. Hallal A, Cohn SM, Namias N, et al. Aerosolized tobramycin in the treatment of ventilator-associated pneumonia:a pilot study. Surg Infect (Larchmt). 2007 Feb;8(1):73–82.
77. Niederman MS, Chastre J, Corkery K, et al. BAY41-6551 achieves bactericidal tracheal aspirate amikacin concentrations in mechanically ventilated patients with gram-negative pneumonia. Intensive Care Med. 2012 Feb;38(2):263–271.
78. Ghannam DE, Rodriguez GH, Raad II, et al. Inhaled aminoglycosides in cancer patients with ventilator-associated gram negative bacterial pneumonia:safety and feasibility in the era of escalating drug resistance. Eur J Clin Microbiol Infect Dis. 2009 Mar;28(3):253–259.
79. Wood GC, Boucher BA, Croce MA, et al. Aerosolized ceftazidime for prevention of ventilator-associated pneumonia and drug effects on the proinflammatory response in critically ill trauma patients. Pharmacotherapy. 2002 Aug;22(8):972–982.
80. Claridge JA, Edwards NM, Swanson J, et al. Aerosolized ceftazidime prophylaxis against ventilator-associated pneumonia in high risk trauma patients:results of a double-blind randomized study. Surg Infect (Larchmt). 2007 Feb;8(1):83–90.
81. Badia JR, Soy D, Adrover M, et al. Disposition of instilled versus nebulized tobramycin and imipenem in ventilated intensive care unit (ICU) patients. J Antimicrob Chemother. 2004 Aug;54(2):508–514.
82. Horianopoulou M, Kanellopoulou M, Paraskevopoulos I, et al. Use of inhaled ampicillin-sulbactam against multi-resistant Acinetobacter baumannii in bronchial secretions of intensive care unit patients. Clin Microbiol Infect. 2004 Jan;10(1):85–86.
83. Kaye KS, Pogue JM, Tran TB, et al. Agents of last resort:polymyxin resistance. Infect Dis Clin North Am. 2016 Jun;30(2):391–414.
84. Liu YY, Wang Y, Walsh TR, et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China:a microbiological and molecular biological study. Lancet Infect Dis. 2016 Feb;16(2):161–168.
85. Zavascki AP, Goldani LZ, Cao G, et al. Pharmacokinetics of intravenous polymyxin B in critically ill patients. Clin Infect Dis. 2008 Nov 15;47(10):1298–1304.
86. Nation RL, Li J, Cars O, et al. Consistent global approach on reporting of colistin doses to promote safe and effective use. Clin Infect Dis. 2014 Jan;58(1):139–141.
87. Kassamali Z, Rotschafer JC, Jones RN, et al. Polymyxins:wisdom does not always come with age. Clin Infect Dis. 2013 Sep;57(6):877–883.
88. Shalini WS, Yapa JL, Kashyap P, et al. Pulmonary and systemic pharmacokinetics of inhaled and intravenous colistin methanesulfonate in cystic fibrosis patients:targeting advantage of inhalational administration. Antimicrob Agents Chemother. 2014;58:2570–2579.
89. Nation RL, Garonzik SM, Li J, et al. Updated US and European dose recommendations for intravenous colistin:how do they perform? Clin Infect Dis. 2016 Mar 1;62(5):552–558.
90. Food And Drug Administration website, Information for Healthcare Professionals:Colistimethate; an alert posted in 2007. [cited 2016 Aug 30]. Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124896.htmb
91. Imberti R, Cusato M, Villani P, et al. Steady-state pharmacokinetics and BAL concentration of colistin in critically Ill patients after IV colistin methanesulfonate administration. Chest. 2010 Dec;138(6):1333–1339.
92. Athanassa ZE, Markantonis SL, Fousteri MZ, et al. Pharmacokinetics of inhaled colistimethate sodium (CMS) in mechanically ventilated critically ill patients. Intensive Care Med. 2012 Nov;38(11):1779–1786.
93. Boisson M, Jacobs M, Grégoire N, et al. Comparison of intrapulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and colistin after aerosol delivery and intravenous administration of CMS in critically ill patients. Antimicrob Agents Chemother. 2014 Dec;58(12):7331–7339.
94. Ioannidou E, Siempos II, Falagas ME. Administration of antimicrobials via the respiratory tract for the treatment of patients with nosocomial pneumonia:a meta-analysis. J Antimicrob Chemother. 2007;60:1216–1226.
95. Florescu DF, Qiu F, McCartan MA, et al. What is the efficacy and safety of colistin for the treatment of ventilator-associated pneumonia? A systematic review and meta-regression. Clin Infect Dis. 2012 Mar 1;54(5):670–680.
96. Valachis A, Samonis G, Kofteridis DP. The role of aerosolized colistin in the treatment of ventilator-associated pneumonia:a systematic review and metaanalysis. Crit Care Med. 2015;43(3):527–533.
97. Liu D, Zhang J, Liu HX, et al. Intravenous combined with aerosolised polymyxin versus intravenous polymyxin alone in the treatment of pneumonia caused by multidrug-resistant pathogens:a systematic review and meta-analysis. Int J Antimicrob Agents. 2015 Dec;46(6):603–609.
98. Panidis D, Markantonis SL, Boutzouka E, et al. Penetration of gentamicin into the alveolar lining fluid of critically ill patients with ventilator-associated pneumonia. Chest. 2005 Aug;128(2):545–552.
99. Burdette SD, Limkemann AJ, Slaughter JB, et al. Serum concentrations of aerosolized tobramycin in medical, surgical and trauma patients. Antimicrob Agents Chemother. 2009 Oct;53(10):4568.
100. Falagas ME, Vouloumanou EK, Samonis G, et al. Fosfomycin. Clin Microbiol Rev. 2016 Apr;29(2):321–347. DOI:10.1128/CMR.00068-15
101. Karageorgopoulos DE, Wang R, Yu XH, et al. Fosfomycin:evaluation of the published evidence on the emergence of antimicrobial resistance in Gram-negative pathogens. J Antimicrob Chemother. [Internet]. 2012;67:255–268. Available from:http://dx.doi.org/10.1093/jac/dkr466
102. Trapnell BC, McColley SA, Kissner DG, et al. Fosfomycin/tobramycin for inhalation in patients with cystic fibrosis with Pseudomonas airway infection. Am J Respir Crit Care Med. 2012 Jan 15;185(2):171–178.
103. Montgomery AB, Vallance S, Abuan T, et al. A randomized double-blind placebo-controlled dose-escalation phase I study of aerosolized amikacin and fosfomycin delivered via the PARI investigational eFlow inline nebulizer system in mechanically ventilated patients. J Aerosol Med Pulm Drug Deliv. 2004 Dec;27(6):441–448.
104. Montgomery AB, Rhomberg PR, Abuan T, et al. Amikacin-fosfomycin at a five-to-two ratio:characterization of mutation rates in microbial strains causing ventilator-associated pneumonia and interactions with commonly used antibiotics. Antimicrob Agents Chemother. 2014 Jul;58(7):3708–3713.
105. Peyrani P, Wiemken TL, Kelley R, et al. Higher clinical success in patients with ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus treated with linezolid compared with vancomycin:Results from IMPACT-HAP study. Crit Care. 2014 Jun 10;18(3):R118.
106. Sullivan BP, El-Gendy N, Kuehl C, et al. Pulmonary delivery of vancomycin dry powder aerosol to intubated rabbits. Mol Pharm. 2015 Aug 3;12(8):2665–2674.
107. Determann RM, Royakkers A, Wolthuis EK, et al. Ventilation with lower tidal volumes as compared with conventional tidal volumes for patients without acute lung injury:a preventive randomized controlled trial. Crit Care. 2010;14(1):R1.
108. Parrilla FJ, Morán I, Roche-Campo F, et al. Ventilatory strategies in obstructive lung disease. Semin Respir Crit Care Med. 2014;35(4):431–440.
109. Maddison J, Dodd M, Webb AK. Nebulized colistin causes chest tightness in adults with cystic fibrosis. Respir Med. 1994;88(2):145–147.
110. Dodd ME, Abbott J, Maddison J, et al. Effect of tonicity of nebulised colistin on chest tightness and pulmonary function in adults with cystic fibrosis. Thorax. 1997;52(7):656–658.
111. Cunningham S, Prasad A, Collyer L, et al. Bronchoconstriction following nebulised colistin in cystic fibrosis. Arch Dis Child. 2001;84(5):432–433.
112. Alothman GA, Alsaadi MM, Ho BL, et al. Evaluation of bronchial constriction in children with cystic fibrosis after inhaling two different preparations of tobramycin. Chest. 2002;122(3):930–934.
113. Konstan MW, Flume PA, Kappler M, et al. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients:the EAGER trial. J Cyst Fibros. 2011;10(1):54–61.
114. Hodson ME, Gallagher CG, Govan JR. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur Respir J. 2002;20(3):658–664.
115. Schuster A, Haliburn C, Döring G, et al. Freedom Study Group Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis:a randomised study. Thorax. 2013;68(4):344–350. PMC free article] [PubMed.
116. Domínguez-Ortega J, Manteiga E, Abad-Schilling C, et al. Induced tolerance to nebulized colistin after severe reaction to the drug. J Investig Allergol Clin Immunol. 2007;17(1):59–61.
117. Falagas ME, Kasiakou SK. Toxicity of polymyxins:a systematic review of the evidence from old and recent studies. Critical Care. 2006;10(1):R27.
118. Dhariwal AK, Tullu MS. Colistin:re-emergence of the ‘forgotten’ antimicrobial agent. J Postgrad Med. 2013;59(3):208–215.
119. Ratjen F, Rietschel E, Kasel D, et al. Pharmacokinetics of inhaled colistin in patients with cystic fibrosis. J Antimicrob Chemother. 2006;57:306–311.
120. MacLeod DL, Nelson LE, Shawar RM, et al. Aminoglycoside-resistance mechanisms for cystic fibrosis Pseudomonas aeruginosa isolates are unchanged by long-term, intermittent, inhaled tobramycin treatment. J Infect Dis. 2000 Mar;181(3):1180–1184.
121. Oermann CM, McCoy KS, Retsch-Bogart GZ, et al. Pseudomonas aeruginosa antibiotic susceptibility during long-term use of aztreonam for inhalation solution (AZLI). J Antimicrob Chemother. 2011 Oct;66(10):2398–2404. DOI:10.1093/jac/dkr303
122. Drobnic ME, Suñé P, Montoro JB, et al. Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa. Ann Pharmacother. 2005 Jan;39(1):39–44.
123. Falagas ME, Siempos II, Bliziotis IA, et al. Administration of antibiotics via the respiratory tract for the prevention of ICU-acquired pneumonia:a meta-analysis of comparative trials. Crit Care. 2006;10(4):R123.
124. Hurley MN, Ariff AH, Bertenshaw C, et al. Results of antibiotic susceptibility testing do not influence clinical outcome in children with cystic fibrosis. J Cyst Fibros. 2012;11(4):288–292.
125. Ehrmann S, Roche-Campo F, Sferrazza Papa G, et al. REVA research network. Aerosol therapy during mechanical ventilation:an international survey. Intensive Care Med. 2013 Jun;39(6):1048–1056.
126. Solé-Lleonart C, Rouby JJ, Chastre J, et al. Intratracheal administration of antimicrobial agents in mechanically ventilated adults:an international survey on delivery practices and safety. Respir Care. 2016 Aug;61(8):1008–1014.
127. Solé-Lleonart C, Roberts JA, Chastre J, et al. ESGCIP Investigators. Global survey on nebulization of antimicrobial agents in mechanically ventilated patients:a call for international guidelines. Clin Microbiol Infect. 2016 Apr;22(4):359–364.
128. Zampieri FG, Nassar AP, Jr, Gusmao-Flores D, et al. Nebulized antibiotics for ventilator-associated pneumonia:a systematic review and meta-analysis. Crit Care. 2015 Apr;7(19):150.
129. Russell CJ, Shiroishi MS, Siantz E, et al. The use of inhaled antibiotic therapy in the treatment of ventilator-associated pneumonia and tracheobronchitis:a systematic review. BMC Pulm Med. 2016 Mar 8;16:40. DOI:10.1186/s12890-016-0202-8.
130. Masterton RG, Galloway A, French G, et al. Guidelines for the management of hospital-acquired pneumonia in the UK:report of the Working Party on hospital-acquired pneumonia of the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother. 2008 jul;62(1):5–34.